Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers (NYSE: HIMS) launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a blood-based multi-cancer early detection (MCED) test that screens for a signal across 50+ types of cancer and predicts likely tissue of origin.
Customers can add the Galleri test to existing Labs plans with a $250 discount off Galleri list price, enabling annual proactive screening alongside recommended tests.
Hims & Hers (NYSE: HIMS) will report fourth quarter and full year 2025 financial results after market close on Monday, February 23, 2026. A live conference call is scheduled for 5:00 p.m. ET, with dial-in details and a live audio webcast at https://investors.hims.com, archived for one year.
Company management will also participate in the Morgan Stanley Technology, Media & Telecom Conference on March 2, 2026 in San Francisco.
Hims & Hers (NYSE: HIMS) returns to the Big Game with a national spot titled “Rich People Live Longer”, airing February 8, 2026. The ad argues that proactive, preventive care should be accessible to all and cites research that the top 1% live seven years longer than the bottom 50%.
The campaign highlights Hims & Hers’ platform features, including Labs testing (routine markers and an early cancer detection test), microdose metabolic treatments, and clinician-guided hormone care. Voice talent includes artist Common to emphasize health equity and awareness.
Hims & Hers (HIMS) launched its Hers platform in the UK on December 10, 2025, extending its comprehensive Weight Loss Programme to eligible British customers.
The digital programme pairs GMC‑registered clinicians with personalised care, 24/7 support, and treatment options that may include branded GLP‑1s (Mounjaro, Wegovy) and oral Orlos after a clinically robust intake assessment. The offering emphasises long‑term lifestyle support across nutrition, movement, and sleep and positions Hers as a women‑focused, telehealth route complementary to NHS services.
Hims & Hers (NYSE: HIMS) announced its official entry into Canada following the completion of its acquisition of Livewell, a Canadian digital health platform focused on weight loss.
The company said the move positions Hims & Hers to expand its digital health footprint and accelerate a comprehensive weight loss program planned for next year, timed with anticipated first availability of generic semaglutide. Hims & Hers named Austin Kouri as General Manager of Canada and Dr. Sandy Van as advisor and Chief Medical Officer in Canada. The acquisition was funded all cash from Hims & Hers’ balance sheet.
Hims & Hers (NYSE: HIMS) announced it is now serving customers in Canada following its acquisition of Livewell, a Canadian digital weight-loss platform. The company said the expansion will accelerate a Canadian launch of its comprehensive weight loss program next year, timed with the anticipated first availability of generic semaglutide. Hims & Hers named Austin Kouri as General Manager of Canada and announced Dr. Sandy Van as Canada chief medical advisor, with Livewell co-founders joining the Canadian leadership team.
The move emphasizes localized leadership, accessible digital care, and planned specialty expansion in Canada.
Hims & Hers (NYSE:HIMS) entered a definitive agreement to acquire YourBio Health, a Boston-based developer of capillary whole blood sampling technology, announced on December 3, 2025.
YourBio’s TAP® device and HALO™ micro-needle system use bladeless microneedles thinner than an eyelash to collect capillary blood samples pain-free in seconds; the technologies are protected by a portfolio of patents. The deal will add the technology and leadership team (Dr. Michael Mina and Paul Owen) to Hims & Hers' platform. The transaction is expected to close in early 2026, is funded entirely with cash from Hims & Hers’ balance sheet, and remains subject to customary regulatory approvals and closing conditions.
Hims & Hers (NYSE: HIMS) announced that its Board authorized a $250 million share repurchase program to buy Class A common stock over the next three years. The program follows the company’s prior $100 million repurchase, which has been fully utilized. Repurchases may occur via open market purchases, privately negotiated transactions or 10b5-1 plans, and the program can be commenced, suspended or discontinued at any time. The company said the program is supported by a strong balance sheet and projected future cash flows and is intended to provide flexibility to act when the market price may not reflect intrinsic value while maintaining focus on growth and innovation.
Hims & Hers (NYSE: HIMS) named Deb Autor as its first Chief Policy Officer on November 17, 2025 to lead global public policy, regulatory, and government affairs.
Autor brings more than three decades of experience, including roles as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, a DOJ trial attorney, Global Head of Regulatory Excellence at AstraZeneca, and CEO of Healthcare Innovation Catalysts. She will remain on the company's Board of Directors.
Hims & Hers (NYSE: HIMS) launched Labs, a subscription testing service that measures biomarkers and provides doctor-developed action plans to help customers monitor and improve health.
Two plans: Base — one annual blood draw, 50 biomarkers across 9 categories, $199/year; Advanced — two draws, 120+ biomarkers across 10 categories, $499/year. Both include clinician-reviewed results and access to personalized treatment plans if appropriate.
The company plans future expansion to at-home devices, additional biomarker panels (bone, brain), and advanced diagnostics to detect chronic and life-threatening conditions.